Evaluation of epidemiologic and animal data associating pesticides with Parkinson's disease

Journal of Occupational and Environmental Medicine

Volumn 47, Issue 10, 2005, Pages 1059-1087

  Li, Abby A ^a   Mink, Pamela J ^a   McIntosh, Laura J ^a   Teta, M Jane ^a   Finley, Brent ^b  

^a EXPONENT INC   (United States)

^b CARDNO CHEMRISK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIELDRIN; HEPTACHLOR; MANEB; PARAQUAT; PERMETHRIN; PESTICIDE; ROTENONE;

CLINICAL FEATURE; DISEASE MODEL; ENVIRONMENTAL EXPOSURE; EVALUATION; HUMAN; INCIDENCE; MEDICAL LITERATURE; MEDLINE; NONHUMAN; OCCUPATIONAL EXPOSURE; PARAMETER; PARKINSON DISEASE; PREVALENCE; PUBLICATION; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; VALIDATION PROCESS;

ANIMALIA;

EID: 27144556141     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000174294.58575.3e     Document Type: Article

References (147)

1. Tanner CM, Ben-Shlomo Y. Epidemiology of Parkinson's disease. Adv Neurol. 1999;80:153-159.
2. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry. 2004; 75:637-639.
3. National Parkinson's Foundation. Parkinson's Disease: Hope through Research. Available at: http://www.ninds. nih.gov/disorders/parkinsons_disease/ detail_parkinsons_disease.htm. Accessed April 2005.
4. Gasser T. Genetics of Parkinson's disease. J Neurol. 2001;248:833-840.
5. Gasser T, Bressman S, Durr A, Higgins J, Klockgether T, Myers RH. State of the art review: molecular diagnosis of inherited movement disorders. Movement Disorders Society task force on molecular diagnosis. Mov Disord. 2003; 18:3-18.
6. Tanner CM, Ottman R, Goldman SM, et al. Parkinson's disease in twins: an etiologic study. JAMA. 1999;281:341-346.
7. Vaughan JR, Davis MB, Wood NW. Genetics of parkinsonism: a review. Ann Hum Genet. 2001;65:111-126.
8. Checkoway H, Nelson LM. Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology. 1999;10:327-336.
9. Marion SA. The epidemiology of Parkinson's disease. Current issues. Adv Neurol. 2001;86:163-172.
10. Rajput AH, Uitti RJ, Stern W, et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci. 1987;14:414-418.
11. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: a meta-analysis. Environ Res. 2001;86:122-127.
12. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol. 1999;56:33-39.
13. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology. 1997;48:1277-1281.
14. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839-840.
15. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292-1295.
16. Perez RG, Hastings TG. Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J Neurochem. 2004;89:1318-1324.
17. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci. 2003;23:3095-3099.
18. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci. 2004;19:845-854.
19. Jellinger KA. The pathology of Parkinson's disease. Adv Neurol. 2001;86: 55-72.
20. Le Couleur DG, McLean AJ, Taylor MC, Woodham BL, Board PG. Pesticides and Parkinson's disease. Biomed Pharmacother. 1999;53:122-130.
21. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet. 1998;352:1344-1346.
22. McCann SJ, LeCouteur DG, Green AC, et al. The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology. 1998;17:310-317.
23. Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology. 1998;19:709-712.
24. Tanner CM, Chen B, Wang W, et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology. 1989;39:660-664.
25. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology. 2000;21:435-440.
26. Chaturvedi S, Ostbye T, Stoessl AJ, Merskey H, Hachinski V. Environmental exposures in elderly Canadians with Parkinson's disease. Can J Neurol Sci. 1995;22: 232-234.
27. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55:181-184.
28. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745-752.
29. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol. 1990;53:245-249.
30. Rothman KJ, Greenland S. Modern Epidemiology. Hagerstown, MD: Lippincott-Raven; 1998.
31. Kelsey JL, Whittemore A, Thompson WD, Evans AS. Methods in Observational Epidemiology. New York: Oxford University Press; 1996.
32. Chan DK, Woo J, Ho SC, et al. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry. 1998;65:781-784.
33. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42:1328-1335.
34. Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology. 1997;48:1583-1588.
35. Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord. 1999;14:28-37.
36. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology. 1993; 43:1693-1697.
37. Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. Acta Neurol Scand. 2002;105:77-82.
38. Duzcan F, Zencir M, Ozdemir F, et al. Familial influence on parkinsonism in a rural area of Turkey (Kizilcaboluk-Denizli): a community-based case-control study. Mov Disord. 2003;18:799-804.
39. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology. 1989;39:1314-1318.
40. Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord. 1990;5:66-70.
41. Zayed J, Ducic S, Campanella G, et al. [Environmental factors in the etiology of Parkinson's disease.] Can J Neurol Sci. 1990; 17:286-291.
42. Taylor CA, Saint-Hilaire MH, Cupples LA, et al. Environmental, medical, and family history risk factors for Parkinson's disease; a New England-based case control study. Am J Med Genet. 1999;88:742-749.
43. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50:1346-1350.
44. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology. 1993;43: 1150-1158.
45. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology. 1996;46:1275-1284.
46. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology. 1993;43:1173-1180.
47. Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord. 1994;9:69-75.
48. Engel LS, Checkoway H, Keifer MC, et al. Parkinsonism and occupational exposure to pesticides. Occup Environ Med. 2001;58:582-589.
49. Elbaz A, Levecque C, Clavel J, et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann Neurol. 2004;55:430-434.
50. Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann Neurol. 2004;55: 897.
51. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics. 2003;13:259-263.
52. Elbaz A, Levecque C, Clavel J, et al. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov Disord. 2003;18:130-137.
53. Hubble JP, Kurth JH, Glatt SL, et al. Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementia. Neuroepidemiology. 1998;17:96-104.
54. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434-442.
55. Hill AB. The environment and disease: association or causation? Proceedings of the Royal Society of Medicine. 1965; 58:295-300.
56. US Surgeon General. Smoking and Health - A Report of the Surgeon General, vol (PHS) 79-50066. Washington, DC: Department of Health, Education, and Welfare; 1979.
57. Walrath J, Rogot E, Murray J, Blair A. Mortality Patterns Among US Veterans by Occupation and Smoking Status. Washington, DC: US Government Printing Office, NIH Pub #85-2756; 1985.
58. Stern M, Dulaney E, Gruber SB, et al. The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. Arch Neurol. 1991;48: 903-907.
59. Herishanu YO, Medvedovski M, Goldsmith JR, Kordysh E. A case-control study of Parkinson's disease in urban population of southern Israel. Can J Neurol Sci. 2001;28:144-147.
60. Uversky VN, Li J. Fink AL. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 2001;500:105-108.
61. Uversky VN, Li J, Bower K, Fink AL. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology. 2002;23:527-536.
62. Manning-Bog AB, McCormack AL, Li J. Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes upregulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem. 2002:277:1641-1644.
63. Dekker MC, Bonifati V, van Duijn CM. Parkinson's disease: piecing together a genetic jigsaw. Brain. 2003;126:1722-1733.
64. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26:719-723.
65. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci. 2003;991: 120-131.
66. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003; 53(suppl 3):S26-36; discussion S36-38.
67. Rea WJ. Pesticides. J Nutr Environ Med. 1996;6:55-124.
68. Hirsch EC, Hoglinger G, Rousselet E, et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neurol Transm Suppl. 2003: 89-100.
69. Hornykiewicz O. Dopamine and Parkinson's disease. A personal view of the past, the present, and the future. Adv Neurol. 2001;86:1-11.
70. Stoessl AJ. Neurochemical and neuroreceptor imaging with PET in Parkinson's disease. Adv Neurol. 2001;86:215-223.
71. Orth M, Tabrizi SJ. Models of Parkinson's disease. Mov Disord. 2003;18: 729-737.
72. Rajput A, Rajput M. Essential tremor and parkinsonism. Adv Neurol. 2003;91: 397-399.
73. Rascol O, Ferreira JJ, Thalamas C, Galitsky M, Montastruc JL. Dopamine agonists. Their role in the management of Parkinson's disease. Adv Neurol. 2001; 86:301-309.
74. Rajput AH. The protective role of levodopa in the human substantia nigra. Adv Neurol. 2001;86:327-336.
75. Calne DB. Parkinson's disease over the last 100 years. Adv Neurol. 2003;91: 1-8.
76. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989;1:1269.
77. Kish SJ, Bergeron C, Rajput A, et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem. 1992;59: 776-779.
78. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem. 1994;63:2179-2184.
79. Brennan WA Jr, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem. 1985;44:1948-1950.
80. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 1996;39:385-389.
81. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 1993;61:2322-2325.
82. Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH Jr, Beal MF. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem. 1998;71:281-287.
83. Chiba K, Trevor AJ, Castagnoli N Jr. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun. 1985;128: 1228-1232.
84. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA. 1985;82:2173-2177.
85. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays. 2002;24:308-318.
86. Kamel F, Hoppin JA. Association of pesticide exposure with neurologic dysfunction and disease. Environ Health Perspect. 2004;112:950-958.
87. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3:1301-1306.
88. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2003;179:9-16.
89. Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res. 2002;136:317-324.
90. Alam M, Mayerhofer A, Schmidt WJ. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Behav Brain Res. 2004;151: 117-124.
91. Fleming SM, Zhu C, Fernagut PO, et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol. 2004;187:418-429.
92. Ferrante RJ, Schulz JB, Kowall NW, Beal MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 1997; 753:157-162.
93. Höglinger GU, Feger J, Prigent A, et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem. 2003; 84:491-502.
94. Higgins DS Jr, Greenamyre JT. [3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study. J Neurosci. 1996:16:3807-3816.
95. Thiffault C, Langston JW, Di Monte DA. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res. 2000;885: 283-288.
96. Lapointe N, St-Hilaire M, Martinoli MG, et al. Rotenone induces non-specific central nervous system and systemic toxicity. Faseb J. 2004;18:717-719.
97. Perier C, Bove J, Vila M, Przedborski S. The rotenone model of Parkinson's disease. Trends Neurosci. 2003;26:345-346.
98. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 1984:311:464-467.
99. Lock EA, Martin FW. Paraquat. In: Krieger R, ed. Handbook of Pesticide Toxicology, vol 2: Academic Press; 2001:1559-1604.
100. Widdowson PS, Farnworth MJ, Simpson MG, Lock EA. Influence of age on the passage of paraquat through the blood-brain barrier in rats: a distribution and pathological examination. Hum Exp Toxicol. 1996:15:231-236.
101. Barlow BK, Thiruchelvam MJ, Bennice L, Cory-Slechta DA, Ballatori N, Richfield EK. Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates. J Neurochem. 2003;85:1075-1086.
102. Foster AJ, Marks L, Lock EA, Sturgess NC. Paraquat is not a substrate for the dopamine transporter and does not bind to dopamine D1 and D2 receptors in the rat and mouse striatum. Toxicology. 2004;202:131-132.
103. Richardson JR, Sherer TB, Greenamyre JT, Miller GW. Mechanism of complex I inhibition by MPP+ and paraquat. Society for Neuroscience Abstracts. 2003:732-733.
104. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 1999;823:1-10.
105. McCormack AL, Di Monte DA. Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem. 2003;85:82-86.
106. McCormack AL, Thiruchelvam M, Manning-Bog AB, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 2002;10:119-127.
107. Thiruchelvam M, McCormack A, Richfield EK, et al. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci. 2003;18:589-600.
108. Thiruchelvam M, Richfield EK, Goodman BM, Baggs RB, Cory-Slechta DA. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology. 2002;23:621-633.
109. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res. 2000;873:225-234.
110. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci. 2000;20:9207-9214.
111. Widdowson PS, Farnworth MJ, Upton R, Simpson MG. No changes in behaviour, nigro-striatal system neurochemistry or neuronal cell death following toxic multiple oral paraquat administration to rats. Hum Exp Toxicol. 1996;15: 583-591.
112. Naylor JL, Widdowson PS, Simpson MG, Farnworth M, Ellis MK, Lock EA. Further evidence that the blood/brain barrier impedes paraquat entry into the brain. Hum Exp Toxicol. 1995;14:587-594.
113. Environmental Protection Agency Office of Pesticide Programs. Available at: http://www.epa.gov/oppsrrd1/REDs/0262red.pdf. 1997.
114. Ferraz HB, Bertolucci PH, Pereira JS, Lima JG, Andrade LA. Chronic exposure to the fungicide maneb may produce Symptoms and signs of CNS manganese intoxication. Neurology. 1988;38;550-553.
115. Meco G, Bonifati V, Vanacore N, Fabrizio E. Parkinson'sism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand J Work Environ Health. 1994;20: 301-305.
116. Zhang J, Fitsanakis VA, Gu G, et al. Manganese ethylene-bis- dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem. 2003;84:336-346.
117. Morato GS, Lemos T, Takahashi RN. Acute exposure to maneb alters some behavioral functions in the mouse. Neurotoxicol Teratol. 1989;11:421-425.
118. Integrated Risk Information System (IRIS). Maneb; CASRN: 12427-38-2. Available at: http://www.epa.gov/iris/subst70249.htm. Accessed April 2005.
119. Hoy JB, Cornell JA, Karlix JL, Tebbett IR, van Haaren F. Repeated coadministrations of pyridostigmine bromide, DEET, and permethrin alter locomotor behavior of rats. Vet Hum Toxicol. 2000;42:72-76.
120. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta. 1998; 1364:222-235.
121. Bloomquist JR, Barlow RL, Gillette JS, Li W, Kirby ML. Selective effects of insecticides on nigrostriatal dopaminergic nerve pathways. Neurotoxicology. 2002;23:537-544.
122. Gillette JS, Bloomquist JR. Differential up-regulation of striatal dopamine transporter and alpha-synuclein by the pyrethroid insecticide permethrin. Toxicol Appl Pharmacol. 2003;192:287-293.
123. Karen DJ, Li W, Harp PR, Gillette JS, Bloomquis JR. Striatal dopaminergic pathways as a target for the insecticides permethrin and chlorpyrifos. Neurotoxicology. 2001;22:811-817.
124. Pittman JT, Dodd CA, Klein BG. Immunohistochemical changes in the mouse striatum induced by the pyrethroid insecticide permethrin. Int J Toxicol. 2003;22:359-370.
125. Abdel-Rahman A, Dechkovskaia AM, Goldstein LB, et al. Neurological deficits induced by malathion, DEET, and permethrin, alone or in combination in adult rats. J Toxicol Environ Health A. 2004;67:331-356.
126. Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol. 1994; 36:100-103.
127. Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D. Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health A. 2000;59:229-234.
128. Kirby ML, Barlow RL, Bloomquist JR. Neurotoxicity of the organochlorine insecticide heptachlor to murine striatal dopaminergic pathways. Toxicol Sci. 2001;61:100-106.
129. Miller GW, Kirby ML, Levey AI, Bloomquist JR. Heptachlor alters expression and function of dopamine transporters. Neurotoxicology. 1999;20:631-637.
130. Purkerson-Parker S, McDaniel KL, Moser VC. Dopamine transporter binding in the rat striatum is increased by gestational, perinatal, and adolescent exposure to heptachlor. Toxicol Sci. 2001;64:216-223.
131. Sharma RP, Winn DS, Low JB. Toxic, neurochemical and behavioral effects of dieldrin exposure in mallard ducks. Arch Environ Contam Toxicol. 1976;5: 43-53.
132. Sharma RP. Influence of dieldrin on serotonin turnover and 5-hydroxyindole acetic acid efflux in mouse brain. Life Sci. 1976;19:537-541.
133. Heinz GH, Hill EF, Contrera JF. Dopamine and norepinephrine depletion in ring doves fed DDE, dieldrin, and Aroclor 1254. Toxicol Appl Pharmacol. 1980;53:75-82.
134. Wagner SR, Greene FE. Dieldrin-induced alterations in biogenic amine content of rat brain. Toxicol Appl Pharmacol. 1978;43:45-55.
135. Sanchez-Ramos J, Facca A, Basit A, Song S. Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. Exp Neurol. 1998;150:263-271.
136. Kitazawa M, Anantharam V, Kanthasamy AG. Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptotic cell death in dopaminergic cells. Free Radic Biol Med. 2001;31:1473-1485.
137. Kitazawa M, Anantharam V, Kanthasamy AG. Dieldrin induces apoptosis by promoting caspase-3-dependent proteolytic cleavage of protein kinase C-delta in dopaminergic cells: relevance to oxidative stress and dopaminergic degeneration. Neuroscience. 2003;119: 945-964.
138. Sherer TB, Richardson JR, Panov AV, Miller GW, Greenamyre JT. Pesticides that inhibit complex I: In vitro toxicity and affinities for the rotenone-binding site in brain mitochondria. Society for Neuroscience Abstracts. 2003;95.18.
139. Sherer TB, Betarbet R, Taylor G, et al. Deguelin, a complex I inhibitor found in Cube' resin, is toxic to neuroblastoma cells and the nigrostriatal dopaminergic pathway. Society for Neuroscience Abstracts. 2004;754.758.
140. Wolf DS, Sherer TB, Richardson JR, et al. Pesticides that inhibit complex I kill cells through an oxidative mechanism. Society for Neuroscience Abstracts. 2003;95.17.
141. Environmental Protection Agency. BASF Corporation, Pesticide Tolerance Petition Filing. Federal Register Environmental Documents, PF-721, FRL-5592-7, 1997.
142. Syngenta Corporation. Available at: http://www.syngentacropprotection-us. com/labels/. Accessed April 2005.
143. US Environmental Protection Agency. Available at: http://www.epa.gov/ oppsrrd1/REDs/0262red.pdf. 1997.
144. Sherer TB, Betarbet R, Testa CM, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003;23:10756-10764.
145. Abdo KM, Eustis SL, Haseman J, Huff JE, Peters A, Persing R. Toxicity and carcinogenicity of rotenone given in the feed to F344 rats and B6C3F1 mice for up to two years. Drug Chem Toxicol. 1988;11:225-235.
146. Hollingworth RM. Inhibitors and uncouplers of mitochondrial oxidative phosphorylation. In: Krieger R, ed. Handbook of Pesticide Toxicology, vol 2. Academic Press; 2001.
147. Acquavella J, Doe J, Tomenson J, Chester G, Cowell J, Bloemen L. Epidemiologic studies of occupational pesticide exposure and cancer: regulatory risk assessments and biologic plausibility. Ann Epidemiol. 2003;13:1-7.